Heathcote, J.

patient lamivudine hbeag hepatitis therapy interferon seroconversion hbeag seroconversion hepatitis b combination study treatment relapse combination therapy monotherapy lamivudine monotherapy hbv dna hepatitis b virus baseline analysis serum lamivudine therapy hbeag seroconversion rate centre group virus hepatitis b infection trial population article antigen level response infection week 52 hepatology professor ymdd variant hbv randomised result hbeag seroconversion rates ifn-lamivudine combination therapy 16 weeks value ifn therapy alanine aminotransferase schalm month combination treatment limit aminotransferase lamivudine 100 mg durability gut.bmj.com 52 weeks glaxo wellcome downloaded event histological pretreatment table interferon monotherapy variant liver factor itt population incidence 0.4 screening multivariate analysis lamivudine treatment combination group alanine evect b c song point pretreatment hbv dna asian b van nunen heathcote